4 Issues To Watch In Amarin's Off-Label Marketing Suit
Amarin Pharma Inc.'s constitutional challenge to U.S. Food and Drug Administration restrictions on off-label marketing will explore important questions for False Claims Act suits and criminal punishment of drugmakers, including free...To view the full article, register now.
Already a subscriber? Click here to view full article